Wei H, Ma BT, Wang YQ, Sang LX, Chang B. Letter to the Editor: Beyond current therapies - any more promising strategies for refractory non-esophageal eosinophilic gastrointestinal diseases? World J Gastrointest Endosc 2026; 18(9): 124355 [DOI: 10.4253/wjge.124355]
Corresponding Author of This Article
Bing Chang, MD, PhD, Chief Physician, Professor, Department of Gastroenterology, The First Affiliated Hospital of China Medical University, No. 155 Nanjing North Street, Shenyang 110001, Liaoning Province, China. cb000216@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
letter
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Wei H, Ma BT, Wang YQ, Sang LX, Chang B. Letter to the Editor: Beyond current therapies - any more promising strategies for refractory non-esophageal eosinophilic gastrointestinal diseases? World J Gastrointest Endosc 2026; 18(9): 124355 [DOI: 10.4253/wjge.124355]
World J Gastrointest Endosc. Sep 16, 2026; 18(9): 124355 Published online Sep 16, 2026. doi: 10.4253/wjge.124355
Letter to the Editor: Beyond current therapies - any more promising strategies for refractory non-esophageal eosinophilic gastrointestinal diseases?
Hong Wei, Bo-Tong Ma, Ying-Qian Wang, Li-Xuan Sang, Bing Chang
Hong Wei, Bo-Tong Ma, Ying-Qian Wang, Bing Chang, Department of Gastroenterology, The First Affiliated Hospital of China Medical University, Shenyang 110001, Liaoning Province, China
Li-Xuan Sang, Department of Gastroenterology, Shengjing Hospital of China Medical University, Shenyang 110022, Liaoning Province, China
Author contributions: Wei H, Sang LX, and Chang B designed the overall concept and outline of the manuscript; Wei H wrote the original draft; Ma BT and Wang YQ revised the manuscript; and all authors have read and approved the final version of the manuscript.
AI contribution statement: Portions of this manuscript were processed using DeepSeek AI tools for translation, language polishing, and word-order adjustments. The authors have carefully reviewed and verified all AI-assisted content and take full responsibility for the scientific integrity of the manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Bing Chang, MD, PhD, Chief Physician, Professor, Department of Gastroenterology, The First Affiliated Hospital of China Medical University, No. 155 Nanjing North Street, Shenyang 110001, Liaoning Province, China. cb000216@163.com
Received: June 12, 2026 Revised: July 28, 2026 Accepted: August 14, 2026 Published online: September 16, 2026 Processing time: 90 Days and 10.7 Hours
Core Tip
Core Tip: This letter comments on a multicenter study of non-esophageal eosinophilic gastrointestinal diseases. High relapse rates after initial response to conventional therapies highlight the need for improved treatment strategies. We suggest the use of endoscopic ultrasound in selected patients with suspected deeper-layer involvement or atypical presentations. Additionally, fecal microbiota transplantation and leukapheresis are suggested as exploratory approaches that warrant further investigation. Given that current evidence is limited to case reports and indirect disease models, additional mechanistic and preclinical studies are urgently needed to evaluate their efficacy and safety and formulate optimal individualized regimens for this disease.
